why choose us

First received: February 26, 2024

Clinical Trial: Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Type2diabetes

Study Type: OBSERVATIONAL


Official Title: Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes: a Cross-sect

Brief Summary: Type 2 diabetes and metabolic (dysfunction)-associated fatty liver disease (MAFLD) often exist together.The prevalence of MAFLD is about 15-30% in healthy people and around 60-70% in people with type 2 diabetes.Moreover, type 2 diabetes accelerates the progression of liver disease in MAFLD.MAFLD is a spectrum of liver conditions, ranging from simple fatty liver (low risk for progression), progressing to steatohepatitis (MASH) with no or mild fibrosis, advanced liver fibrosis, cirrhosis, and hepatocellular…

Read more